The US Food and Drug Administration (FDA) has approved Sanofi's Cablivi as the first treatment for adult patients with a rare blood clotting disorder, acquired thrombotic thrombocytopenic purpura (aTTP).Original Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.